MAPT and Alzheimer disease: The exacerbated mitochondrial dysfunction that ensues in symptomatic AD outcomes in humans can theoretically be ameliorated through (i) direct tau binding and reduced tau oligomerization, (ii) direct radical scavenging to curb mitochondrial ROS production, and (iii) targeting bioenergetic efficiency directly in an attempt to rescue failing neurons (Fatouros et al., 2012; Anand et al., 2014; Guerreiro and Bras, 2015).